Favrille Raises Funding For Expansion

San Diego-based biopharmaceuticals firm Favrille said Friday that the company has raised $20M in a line of credit from GE Capital and Oxford Financial. Favrille said that the debt financing will be used to expand its facilities for the commercial-scale manufacturing of its Phase 3 product candidate, targeted at treatment of non-Hodgkin's lymphoma. The company said that its expanded facilitiy will include 80,000 square feet dedicated to manufacturing. Favrille is developing immunotherapies for the treatment of cancer.